Pages

Kamis, 10 Desember 2020

Coronavirus vaccine trials of candidate developed by UQ and CSL to be abandoned - ABC News

Clinical trials of a COVID-19 vaccine being developed by the University of Queensland in partnership with biotech company CSL will be abandoned, the ABC understands.

The vaccine is one of four the Federal Government had committed to purchasing, and agreements had been made to secure 51 million doses of the vaccine.

A statement is expected to be made to the ASX 200 shortly and UQ and CSL will hold a media conference with further details at 9:00am AEDT.

Just last month, Health Minister Greg Hunt said the vaccine could be widely available by late 2021 after early trials showed promising signs.

"The initial data is very clear, that the [UQ] vaccine is proving to be safe through phase-one clinical trials and it's proving to produce a positive antibody response," Mr Hunt said at the time.

Human trials began in July with 120 volunteers in Brisbane.

The vaccine has been manufactured at CSL's biologics facility in Victoria and was developed using an existing UQ technology called a "molecular clamp".

Federal frontbencher David Littleproud told Channel Nine the Government's multi-vaccine strategy is specifically designed to spread the risk.

"This is why we didn't put all our eggs in one basket," he said.

"This is why we made sure there were four contracts we signed to make sure that we got a vaccine, and this is intrinsically very difficult science that UQ and around the world is trying to break.

"I think UQ, I wouldn't write them off yet, but I think this backs what the Government has done."

The ABC has approached CSL, the University of Queensland and the Federal Government for comment.

Let's block ads! (Why?)


https://news.google.com/__i/rss/rd/articles/CBMiYGh0dHBzOi8vd3d3LmFiYy5uZXQuYXUvbmV3cy8yMDIwLTEyLTExL3VxLWNzbC1jb3JvbmF2aXJ1cy12YWNjaW5lLXRyaWFsLXRvLWJlLWFiYW5kb25lZC8xMjk3MzY1NtIBJ2h0dHBzOi8vYW1wLmFiYy5uZXQuYXUvYXJ0aWNsZS8xMjk3MzY1Ng?oc=5

2020-12-10 19:47:00Z
52781237524179

Tidak ada komentar:

Posting Komentar